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OBJECTIVE: The aim of this study is to verify the expression of proteins that are controlled by miR-let7c, 100 and
218 using immunohistochemistry in tissue microarray representative of localized and metastasized the lymph
nodes and bone prostate cancer.
METHODS: To verify the expression of proteins that are controlled by miR-let7c (C-MYC, BUB1, RAS) 100
(SMARCA5, RB) and 218 (LAMB3) and cell proliferation (Ki-67) we used immunohistochemistry and
computerized image system ImageJ MacBiophotonics in three tissue microarrays representative of localized
prostate cancer and lymph node and bone metastases. miRNA expression was evaluated by qRT-PCR using 60
paraffin blocks to construct the tissue microarray representative of localized disease.
RESULTS: RAS expression was increased in localized prostate cancer and bone metastases compared to the
lymph nodes (p= 0.017). RB showed an increase in expression from localized prostate cancer to lymph node and
bone metastasis (p = 0.036). LAMB3 was highly expressed in localized and lymph node metastases (p,0.001).
Cell proliferation evaluated by Ki-67 showed an increase from localized prostate cancer to metastases
(p,0.001). We did not found any relationship between C-MYC (p=0.253), BUB1 (p=0.649) and SMARCA5
(p=0.315) protein expression with prognosis or tumor behavior.
CONCLUSION: We found that the expression of RAS, RB, LAMB3 and Ki-67 changed in the different stages of
prostate cancer. Furthermore, we confirmed the overexpression of the miRNAs let7c, 100 and 218 in localized
prostate cancer but failed to show the control of protein expression by the putative controller miRNAs using
immunohistochemistry.
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& INTRODUCTION
Prostate cancer (PC) is a common disease with a multi-
factorial and complex etiology. PC is the most common male
malignancy and the second leading cause of death among
men in many countries, including Brazil. In the United
States, 241,740 new cases and 28,170 deaths related to PC are
estimated for the year 2012 (1).
The widespread use of prostate-specific antigen (PSA) has
increased prostate cancer detection rates at earlier stages.
However, up to 20% of clinically localized cases recur
during a 10-year follow-up period after local radical
treatment. In addition, current clinical and pathological
parameters fail to determine an accurate prognosis in many
cases (2). Prior identification of patients with poor prog-
noses is of paramount importance in clinical practice,
especially for determining whether additional treatments
are necessary. Currently, there are no clinical parameters or
molecular markers that can accurately assess the aggressive
behavior and metastatic potential of PC. Nevertheless, both
tumor invasion and progression to metastasis, which are the
signatures of malignancy, are related to cell proliferation
and chromosomal stability.
We have recently described alterations in the expression
profile of micro RNAs (miRNAs) during the progression
from localized to metastatic PC characterized by the loss of
expression of miR-let7c, miR-100 and miR-218 (3). miRNAs
are a class of noncoding RNAs responsible for the control of
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one third of the human genes involved in many carcino-
genic processes. C-MYC, RAS and BUB1 are the target genes
for miR-let7c (4,5) while SMARCA5 and Retinoblastoma
(RB) are the target genes for miR-100 (http://
atlasgeneticsoncology.org/Genes/MIR100ID51447ch11q24.
html) and Laminin 5 b3 (LAMB3) is the target for miR-218
(6).
C-MYC is a multifunctional, nuclear phosphoprotein that
plays a role in cell cycle progression, apoptosis and cellular
transformation; this protein also functions as a transcription
factor that regulates the transcription of specific target genes
(7). The RAS protein functions as a binary molecular switch
that controls intracellular signaling networks involved in
cytoskeletal integrity, cell proliferation, differentiation,
adhesion, apoptosis, and migration (8). Bub-1 is a kinase
protein involved in spindle checkpoint by phosphorylating
a member of the mitotic checkpoint complex (9). SMARCA5
mediates DNA accessibility by sliding the histone octamer,
which is important for gene expression, DNA replication,
DNA repair, and the maintenance of the chromatin
structure (10). The RB protein is a key negative regulator
of the cell cycle and an important tumor suppressor gene
(11). Finally, LAMB3 and its ligand a6b4-integrin have a role
in cell migration, and their expression has been related to
cell transformation in SCID mice (12).
The aim of this study was to verify the expression of
proteins that are controlled by miR-let7c, 100 and 218 using
immunohistochemistry (IHC) in tissue microarrays (TMA)
representative of both localized PC and PC that had
metastasized to the lymph nodes and bone.
& METHODS
Patients
For the representative TMA of localized PC, we retro-
spectively evaluated 954 patients with clinically localized
PC who underwent radical prostatectomy with a curative
intention between January 1994 and April 2000; from this
population, we randomly selected the patients of our study.
All the surgeries were performed by the same surgeon (MS).
The cohort consisted of 45 cases with biochemical recur-
rence after surgery and 67 cases without recurrence. The
mean age was 63.6 years, the mean PSA was 10.8 ng/mL
and the mean Gleason score was 7.2. The patients were
followed for a median of 79 months. Ninety-seven percent
of patients were Caucasian, and 2.7% were Asian. Tumor
recurrence was defined as a PSA level above 0.4 ng/ml. The
tumor-node-metastasis (TNM) staging designations were
assigned according to the TNM 2010 classification. For the
construction of the second TMA, 19 cases of lymph node
metastases were selected from 1,619 patients who under-
went radical prostatectomy between March 1997 and July
2006. The mean age was 66 years, the mean PSA was 11.9
ng/mL, and the mean Gleason score was 8.8. The slides
containing the metastasis and the primary tumor for each
patient were selected by considering the area that best
represented the whole tumor. One area from the metastasis
and two areas from the primary tumor were selected and
marked with permanent ink; these areas correspond to
those included in the TMA. The third TMA consisted of
twenty-eight patients with a mean age of 67.3 years, a mean
PSA of 553 ng/mL and a mean Gleason score was 8.3. This
cohort of patients had PC bone metastases (femur = 16,
iliac = 2, vertebra = 6, scapula = 2, humerus = 1, and
pubis = 1) and had undergone surgery for the treatment of
secondary bone events at the Orthopedic Institute of the
Hospital das Clı´nicas da Faculdade de Medicina da
Universidade de Sa˜o Paulo (HCFMUSP). This study con-
formed to the provisions of the Declaration of Helsinki and
was submitted to and approved by the Ethical Board of the
Hospital das Clı´nicas da Faculdade de Medicina da
Universidade de Sa˜o Paulo under protocol 1074/04.
Immunohistochemical study
The TMA were constructed on Superfrost slides. The
samples underwent a heat antigen retrieval process using
citrate buffer (1 mM, pH 6.0). The slides were incubated
overnight at 4 C˚ with the monoclonal antibodies specified in
Table 1. The LSAB system was used for immunostaining
(Dako Cytomation, CA). Color was developed by a reaction
with a 3,39diaminobenzidine substrate-chromogen solution
followed by counterstaining with Harris hematoxylin. The
slides were dehydrated, coverslipped and observed under a
light microscope. Cytokeratin 18 was used to test the
preservation of the antigens, and it was strongly positive
in all cases.
Computerized analysis of the immunohistochemical
reactions
The expression of each marker was evaluated by one
pathologist (KRML). The images were captured by an optical
microscope with a 40 6 objective (Nikon Eclipse E200)
coupled to a camera (Nikon DsFi1) using the software NIS-
Elements D 3.1. The luminescence images were quantified
densitometrically using the ImageJ MacBiophotonics
(National Institutes of Health, U.S.) software package
‘‘plug-ins’’ developed by McMaster University (http://
www.macbiophotonics.ca/ImageJ). The antibodies that
bound to nuclear proteins (C-MYC, SMARCA5) were
evaluated by the percentage of stained nuclei, and the
antibodies that bound to cytoplasmic proteins (Bub 1, RAS
and Lamb3) were evaluated as an arbitrary unit correspon-
dent to the area occupied by stained tumor cells; Ki-67 was
used to establish the proliferative index.
MiRNA expression
To compare the miRNA expression with the expression of
the associated target proteins, we evaluated the miRNA
expression by qRT-PCR using 60 paraffin blocks that were
used for the construction of the TMA representative of
localized disease as previously described (4). Briefly, small
RNA fractions were isolated and enriched using a mirVana
miRNA isolation kit (Ambion, Austin, TX), and the
cDNA was obtained using a TaqManH miRNA Reverse
Table 1 - Antibodies used in TMAs representatives of loca-
lized and metastatic prostate cancer to lymph nodes and
bones.
Antibody Clone Brand
RAS F132 Santa Cruz





SMARCA5 H-300 Santa Cruz
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Transcription kit (Applied Biosystems, Foster City, CA).
Next, 10 ng of miRNA was reverse-transcribed using
sequence-specific stem-loop primers to the has-miR-let7c,
hsa-miR-100 and hsa-miR-218 genes. The reaction was
performed in 9600 Emulation mode with the following
parameters: 30 min at 16 C˚, 5 min at 42 C˚, 5 min at 85 C˚ and
4 C˚ until analysis. Quantitative RT-PCR was carried out
using the ABI 7500 Fast Real-Time PCR System and a
Taqman Universal PCR Master Mix (Applied Biosystems,
Foster City, CA). The expression of the individual miRNAs
mentioned above was analyzed using miRNA sequence-
specific primers. These miRNAs were selected for verifica-
tion based on their predicated target genes listed in the
Sanger miRBase database (http://microrna.sanger.ac.uk/
sequences) (13). miRNA expression levels were assessed by
relative quantification, and the fold expression changes
were determined by the 22DDCT method (14). All RT-PCRs
were performed in duplicate, and the small nucleolar RNA
RNU43 was used as the endogenous control.
Statistical analysis
Statistical analyses were performed with SPSS 19.0 for
Windows, and all reported p-values are two sided.
Comparisons of the miRNA and protein expression levels
were performed using Student’s t and Mann-Whitney tests
for homogenous and heterogeneous variables, respectively.
For comparison among three or more variables, we used an
ANOVA test or the Kruskal-Wallis test for homogenous and
heterogeneous variables, respectively. A Chi-squared test
was used to compare nominal scale values. A p-value#0.05
was considered statistically significant.
& RESULTS
Statistical analysis showed that RAS expression was
significantly increased in localized PC (124.93) compared
to the lymph nodes (17.64) and that there was an increase in
expression when the PC metastasized to the bones (104.04)
(p = 0.017). RB showed an increase in expression from
localized PC (12.5%) to lymph node and bone metastases
(25.7% and 20.2%, respectively; p = 0.036). LAMB3 was
highly expressed in localized PC (127.3) and lymph node
metastases (132.5), but the expression was low in the bone
metastases (9.2) (p,0.001). Cell proliferation using Ki-67
increased from localized PC (11.2%) to the lymph node
metastasis (22.3%) and bone metastasis (42.5%) (p,0.001).
C-MYC, Smarca-5 and Bub-1 expression did not show
differences during PC progression (p = 0.253, p = 0.315 and
p= 0.649, respectively) (Table 2 and Figure 1).
We confirmed the overexpression of miR-let7c, 100 and
218 by qRT-PCR. The results are expressed in Figure 2. MiR-
100 and 218 were overexpressed in 98.4% of the cases, and
miR-let7c was overexpressed in 91.8% of the cases. The IHC
expression levels of the proteins were compared to the mean
expression of miRNAs, and no statistical relationship was
detected for the results that are shown in Table 3.
& DISCUSSION
Carcinoma of the prostate can vary greatly in biological
behavior, ranging from slowly progressive to highly
aggressive metastasizing tumors. The introduction of PSA
into clinical practice allowed PC to be diagnosed in its early
stages, increasing the chances of cure with appropriate
treatment. However, 20 to 30% of patients still suffer
recurrence after surgery and commonly receive a salvage
therapy, such as radiotherapy; however, the disease-free
survival rate decreases considerably at this time (2).
Therefore, understanding which factors contribute to the
prognosis of PC is of paramount importance.
The establishment of biomarkers that reflect crucial
biological functions in oncogenesis, such as cell cycling,
proliferation and chromosomal instability, would enable
better prognostication. We hypothesized that changes in
RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67
expression would be related to these events.
In this study, we found that the expression of RAS, RB,
LAMB3 and Ki-67 changed in different stages of PC. There
was an increase in proliferation during tumor progression
reflected by the higher percentage of Ki-67 expression in
bone metastases, followed by lymph node metastases and
finally the primary tumors. Ki-67 is a nuclear antigen
present throughout the whole cell cycle (G1, S, G2 and M
phases) except during the rest phase (GO phase) or in the
early G1 phase (15). Ki-67 nuclear staining has been related
to biological aggressiveness and prognosis in several
cancers, and a greater proliferative index indicates more
aggressive behavior of the neoplasia (16). Ki-67 is a reliable
marker of cellular proliferation that correlates well with the
uptake of bromodeoxyuridine and thymidine labeling (17).
Statistically significant differences in the mean Ki-67 indices
of benign prostatic hyperplasia and prostate cancer have
been uniformly reported (18,19). Previous studies of Ki-67
staining in prostate cancer have shown a variable relation-
ship with tumor stage and grade; however, significant
associations have been found between Ki-67 expression and
the time to progression, metastatic status and tumor volume
(20–22).
Table 2 - Immunohistochemical analyses of proteins that are target of miR-let7c, miR-100 and miR-218. The nuclear stai-
ning was evaluated as percentage of positive nuclei whereas cytoplasmic expression was evaluated as an arbitrary unit
correspondent to the area occupied by tumor cells.
Antibody Localized prostate cancer Lymph node metastasis Bone metastasis p-value
RAS** 124.9 17.6 104.0 0.017
RB* 12.5% 25.7% 20.2% 0.036
LAMB3** 127.3 132.5 9.2 ,0.001
Ki-67* 11.2% 22.3% 42.5% ,0.001
C-MYC* 40.2% 57.3% 51.7% 0.253
BUB1** 164.65 144.2 152.6 0.649
SMARCAR5* 68.0% 48.4% 80.5% 0.315
*percentage of stained nuclei.
**arbitrary unit correspondent to the area occupied by tumor cells.
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We were unable to show a correlation between the
expression of proteins related to the control of cell
proliferation and Ki-67 expression. RAS was highly
expressed in localized PC; however, a significant decrease
in the expression was observed in the lymph node
metastases that was regained in the bone metastases. The
family of RAS oncogenes has been extensively studied for
their involvement in the multistep process of carcinogenesis
(23). Overexpression of RAS oncogenes has also been
detected in several human cancers, including breast, colon,
bladder and lung, and has been associated with the
development of the disease (24). RAS activation is impli-
cated in human carcinogenesis mainly by inhibiting
apoptosis and promoting cellular proliferation. However,
there is considerable evidence that the activated RAS
oncogene can also have the opposite action by promoting
apoptosis and inhibiting cellular proliferation. Furthermore,
this oncogene may have an oncosuppressive role under
Figure 1 - 1) Cytoplasmic and nuclear immunoexpression of BUB1 in localized prostate cancer (A and B), in lymph node metastases (C),
and in bone metastases (D). 2) Nuclear immunoexpression of c-C-MYC in localized prostate cancer (A and B), in lymph node metastases
(C), and in bone metastases (D). 3) Nuclear (A) and cytoplasmic (B) immunoexpression of RAS in localized prostate cancer, in lymph
node metastases (C), and in bone metastases (D). 4) Nuclear immunoexpression of RB in normal prostate glands (A), in localized
prostate cancer (B), in lymph node metastases (C), and in bone metastases (D). 5) Nuclear immunoexpression of SMARCA5 in localized
prostate cancer (A and B), in lymph node metastases (C), and in bone metastases (D). 6) Immunoexpression of LAMB3 in the basal
membrane (A) and cytoplasmic staining in localized prostate cancer (B), in lymph node metastases (C), and in bone metastases (D). 7)
Nuclear Ki-67 immunoexpression in localized prostate cancer (A), in the lymph node (B), and in bone metastasis (C).
Figure 2 - Expression of miR-let7c, miR-100 and miR-218 in 60 cases of localized prostate cancer as part of a TMA to evaluate the protein
immunoexpression of their supposed target genes.
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many circumstances. Therefore, we argue that RAS is
important for local tumor growth, but it is not essential
for tumor progression, as it is secondary during invasion
and metastases processes (25).
RB responds in part to the presence of mitogenic signals
and controls the cell cycle mainly during the transition from
G0 to S by binding and inactivating transcription factors.
Comparing the RB expression between normal prostate
tissue and PC, we could see an enormous loss of staining;
however, the PC progression from local tissue to the
metastases was accompanied by an increase in RB expres-
sion. We believe that this increase is a reactive process
associated with the increase in cell proliferation. Ambrosch
et al. (26) have also shown a loss in the expression of RB in
head and neck carcinomas, but this loss was independent of
tumor progression. Maddison et al. (27) showed in an in
vivo model that the loss of RB induces cell proliferation in
the prostate without a transformation; this finding rein-
forces the fact that RB is important for the control of cell
proliferation but may not be related to tumor progression
and metastasization.
LAMB3 was maintained in localized and lymph node
metastases but was almost completely absent in the bone
metastases. Hao et al. (28) have previously shown the same
phenomenon in prostate cancer. LAMB3 is a glycoprotein
abundant in the basal membrane with important biological
activities involved in cell adhesion, migration, angiogenesis
and metastasization (29). In the prostate, LAMB3 is
expressed in normal and tumoral tissues but as different
isoforms. LM332 is predominant in normal prostate tissue
(30), and its expression levels decrease during tumor
progression. The authors believe that the loss of this specific
isoform promotes a crucial change in the extra-cellular
matrix that turns it into a weaker environment conducive to
metastatic dissemination.
In conclusion we found that the expression of RAS, RB,
LAMB3 and Ki-67 changed in the different stages of prostate
cancer. Furthermore, we confirm that miRNAs let7c, 100
and 218 are overexpressed in localized PC but failed to
show the control of protein expression by the supposed
controller miRNAs. We believe that the regulation of these
miRNAs is subtle and not detectable by IHC. Protein
expression control is not a binary system, and no evidence
of a loss of protein expression related to miRNA expression
was detected even with computerized image analysis.
Therefore, western blot analysis may be more suitable for
the evaluation of the control of proteins by miRNAs.
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